84 related articles for article (PubMed ID: 15933230)
1. Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Shimo T; Ashizawa N; Matsumoto K; Nakazawa T; Nagata O
Toxicol Sci; 2005 Sep; 87(1):267-76. PubMed ID: 15933230
[TBL] [Abstract][Full Text] [Related]
2. Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Shimo T; Ashizawa N; Moto M; Iwanaga T; Nagata O
Arch Toxicol; 2011 May; 85(5):505-12. PubMed ID: 20936465
[TBL] [Abstract][Full Text] [Related]
3. FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.
Shimo T; Ashizawa N; Moto M; Matsumoto K; Iwanaga T; Nagata O
Toxicol Pathol; 2009 Jun; 37(4):438-45. PubMed ID: 19336671
[TBL] [Abstract][Full Text] [Related]
4. Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Ashizawa N; Shimo T; Matsumoto K; Oba K; Nakazawa T; Nagata O
Toxicol Appl Pharmacol; 2006 Dec; 217(3):260-5. PubMed ID: 17084874
[TBL] [Abstract][Full Text] [Related]
5. Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Ashizawa N; Shimo T; Matsumoto K; Taniguchi T; Moto M; Nagata O
Drug Chem Toxicol; 2011 Apr; 34(2):151-61. PubMed ID: 21105859
[TBL] [Abstract][Full Text] [Related]
6. Study on toxicological aspects of crystal-mediated nephrotoxicity induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Shimo T; Moto M; Ashizawa N; Oba K; Nagata O
Drug Chem Toxicol; 2011 Apr; 34(2):192-8. PubMed ID: 21314469
[TBL] [Abstract][Full Text] [Related]
7. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors.
Shimo T; Moto M; Ashizawa N; Matsumoto K; Iwanaga T; Saito K
Arch Toxicol; 2014 Apr; 88(4):1035-42. PubMed ID: 24448833
[TBL] [Abstract][Full Text] [Related]
8. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
Matsumoto K; Okamoto K; Ashizawa N; Nishino T
J Pharmacol Exp Ther; 2011 Jan; 336(1):95-103. PubMed ID: 20952484
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.
Nakazawa T; Miyata K; Omura K; Iwanaga T; Nagata O
Drug Metab Dispos; 2006 Nov; 34(11):1880-6. PubMed ID: 16914512
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
11. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Horiuchi H; Ota M; Kobayashi M; Kaneko H; Kasahara Y; Nishimura S; Kondo S; Komoriya K
Res Commun Mol Pathol Pharmacol; 1999; 104(3):307-19. PubMed ID: 10741381
[TBL] [Abstract][Full Text] [Related]
12. Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol.
Ricardo SD; Bertram JF; Ryan GB
Exp Nephrol; 1995; 3(5):270-9. PubMed ID: 7583048
[TBL] [Abstract][Full Text] [Related]
13. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.
Fukunari A; Okamoto K; Nishino T; Eger BT; Pai EF; Kamezawa M; Yamada I; Kato N
J Pharmacol Exp Ther; 2004 Nov; 311(2):519-28. PubMed ID: 15190124
[TBL] [Abstract][Full Text] [Related]
14. Toxicology and Carcinogenesis Studies of Mercuric Chloride (CAS No. 7487-94-7) in F344 Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Feb; 408():1-260. PubMed ID: 12621522
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
18. Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats.
Minami M; Ishiyama A; Takagi M; Omata M; Atarashi K
Blood Press; 2005; 14(2):120-5. PubMed ID: 16036490
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 1,4-Dichlorobenzene (CAS No. 106-46-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1987 Jan; 319():1-198. PubMed ID: 12748734
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Sato T; Ashizawa N; Matsumoto K; Iwanaga T; Nakamura H; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Nov; 19(21):6225-9. PubMed ID: 19783139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
